Objective: Overlap syndromes have been described between N‐methyl‐ d‐aspartate receptor encephalitis (NMDARE) and other neuroinflammatory conditions, although rarely involving neurosarcoidosis. Molecularly targeted immunotherapy may be helpful in the empiric treatment of these conditions.Methods: We describe a 9‐year‐old boy with new‐onset seizures and worsening encephalopathy.Results: Initial evaluation was concerning for neurosarcoidosis, including elevated cerebrospinal fluid (CSF) and serum angiotensin‐converting enzyme and leptomeningeal with multiple cranial nerve enhancement on magnetic resonance imaging. CSF and serum cytokine profiles were used to choose targeted empiric immunotherapy, and the boy's seizure burden and encephalopathy improved after treatment with tocilizumab. The NMDA receptor antibody titer was later found to be elevated, raising suspicion for a novel overlap syndrome.Interpretation: Our patient met the criteria for definite NMDARE and possible neurosarcoidosis. Given the mixed radiographic and serologic markers in this child, cytokine levels were used to direct the choice of empiric treatment, resulting in excellent clinical response. This case suggests that targeted immunotherapy informed by cytokine testing may be helpful in cases of high‐acuity pediatric neuroinflammatory disease with limited diagnostic clarity.
Background: Peripheral nerve blocks (PNBs), while an effective treatment of headache disorders in adults, have been infrequently studied in pediatric patients. This study aimed to assess practice patterns in PNB use in pediatric headache.Methods: This was a prospective study conducted between 2020 and 2022 in a headache clinic at a tertiary children’s hospital. Pre- and post-injection survey data were prospectively obtained from 16 patients over 32 visits where PNBs, including greater and lesser occipital, auriculotemporal, supraorbital, and supratrochlear nerve blocks, were administered.Results: Participants ranged in age from 10 to 19 years old, with a median age of 16.7 years, and the majority were diagnosed with migraine without aura. Among the total cohort, mean pain scores, obtained on a 10-point scale, decreased from 4.4 pre-injection to 2.8 post-injection (p=0.003). When stratified by specific headache diagnosis, only patients with migraine without aura reported significant pain decrease (p=0.007).Conclusion: These preliminary findings support that PNBs may be a promising treatment in pediatric headache, particularly in migraine without aura.